Palisade Bio Inc. Insider Trading

PALI

Last 12 months

Insiders bought 297K and sold 421K on the open market.

None of the selling was scheduled in advance under a 10b5-1 plan. CEO, CFO John David Finley sold 304K on Jul 7, 40% of their stake, outside a plan.

Net open-market

−124K

6 buys · 4 sales

Under a 10b5-1 plan

of the value sold

Insiders who bought / sold

2 / 2

executives and directors

Last open-market buy

Oct 2026

Oct 2, 2026

Get an email when PALI's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Oct 1 – 2	Donald Allen Williams Director	Bought 2 parts	20,000	$1.44 average	29K	1.3%	Form 4
Jul 8 – 9	Robert Baltera Jr. Director	Bought 2 parts	45,000	$1.97 average	89K	11%	Form 4
Jul 6 – 7	Robert Baltera Jr. Director	Bought 2 parts	50,000	$2.04 average	102K	14%	Form 4
Jul 7	Mitchell Lawrence Jones Chief Medical Officer	SoldNo plan	51,880	$2.05	106K	36%	Form 4
Jul 7	John David Finley CEO, CFO	SoldNo plan	146,798	$2.07	304K	40%	Form 4
Jul 1 – 2	Robert Baltera Jr. Director	Bought 2 parts	30,000	$1.98 average	59K	8.9%	Form 4
Feb 12	Mitchell Lawrence Jones Chief Medical Officer	SoldNo plan	1,989	$1.75	3K	13%	Form 4
Feb 12	John David Finley CEO, CFO	SoldNo plan	3,896	$1.75	7K	12%	Form 4
Jan 16	Donald Allen Williams Director	Bought	5,000	$1.67	8K	57%	Form 4
Jan 9	Donald Allen Williams Director	Bought	5,000	$1.88	9K	134%	Form 4

Oct 1 – 2
Donald Allen Williams
Director · bought 20,000 at avg $1.44
29K
1.3% of stake
Jul 8 – 9
Robert Baltera Jr.
Director · bought 45,000 at avg $1.97
89K
11% of stake
Jul 6 – 7
Robert Baltera Jr.
Director · bought 50,000 at avg $2.04
102K
14% of stake
Jul 7No plan
Mitchell Lawrence Jones
Chief Medical Officer · sold 51,880 at $2.05
106K
36% of stake
Jul 7No plan
John David Finley
CEO, CFO · sold 146,798 at $2.07
304K
40% of stake
Jul 1 – 2
Robert Baltera Jr.
Director · bought 30,000 at avg $1.98
59K
8.9% of stake
Feb 12No plan
Mitchell Lawrence Jones
Chief Medical Officer · sold 1,989 at $1.75
3K
13% of stake
Feb 12No plan
John David Finley
CEO, CFO · sold 3,896 at $1.75
7K
12% of stake
Jan 16
Donald Allen Williams
Director · bought 5,000 at $1.67
8K
57% of stake
Jan 9
Donald Allen Williams
Director · bought 5,000 at $1.88
9K
134% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch PALI, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Biological Products, (No Diagnostic Substances) · Pick stocks to compare with PALI

CompareIntrinsic value

CRDFCardiff Oncology Inc.

$0.87+1.03%36

ARMPArmata Pharmaceuticals Inc.

$3.14+1.62%30

BCABBioAtla, Inc.

$2.00+0.00%0

CVMCel-Sci Corporation

$1.38-2.13%0

ZIVOZivo Bioscience Inc.

$8.00+10.34%0

IMAImageneBio, Inc.

$4.10+1.99%10

WINTWindtree Therapeutics Inc.

$0.00+0.00%10

ATYRAtyr Pharma Inc.

$6.18-6.79%10

Held by ETFs

PALI is in 3 US ETFs. The largest of them, with PALI's weight in each:

Spot a number that looks wrong? Check it in PALI's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing PALI

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.